Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07695298 · ClinicalTrials.gov registry record · Phase 4
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
A Phase 4 study, sponsored by Cincinnati Eye Institute, Southwest Ohio.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT07695298: Recruiting Phase 4 study, sponsored by Cincinnati Eye Institute, Southwest Ohio.
NCT07695298 is a Phase 4 study that is actively recruiting participants, run by Cincinnati Eye Institute, Southwest Ohio. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07695298, a Phase 4 study, is actively recruiting participants, sponsored by Cincinnati Eye Institute, Southwest Ohio.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis (POHS)
Primary Outcome
To assess central macular subfield thickness (CST) change from baseline to week 52.
Interventions
- DRUG Faricimab Injection [Vabysmo]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-05 |
| Phase | Phase 4 |
What NCT07695298 shows while recruiting
NCT07695298 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Faricimab Injection [Vabysmo] is the first listed.
NCT07695298 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07695298 about?
NCT07695298 is a clinical study titled "A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome". This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related t...
What is the current status of trial NCT07695298?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2026-07. Estimated completion is 2028-05.
What interventions are being tested in trial NCT07695298?
The interventions under investigation include: Faricimab Injection [Vabysmo] (DRUG).
Who is sponsoring clinical trial NCT07695298?
This trial is sponsored by Cincinnati Eye Institute, Southwest Ohio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07695298's enrollment target sits among peer trials
25 1669th of 2000 higher than 302 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia